ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
CYduct Diagnostics Inc (PK)

CYduct Diagnostics Inc (PK) (CYDX)

0.1511
0.00
(0.00%)
Closed 10 December 8:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.1511
Bid
0.1264
Offer
0.535
Volume
-
0.00 Day's Range 0.00
0.127 52 Week Range 0.532
Market Cap
Previous Close
0.1511
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
264
Shares Outstanding
5,240,857
Dividend Yield
-
PE Ratio
-1.88
Earnings Per Share (EPS)
-0.08
Revenue
84k
Net Profit
-418k

About CYduct Diagnostics Inc (PK)

CYduct Diagnostics, Inc., headquartered in Westport, Connecticut, develops, produces, and markets medical products for the assessment, identification, diagnosis and ultimately treatment of early-stage breast disease. CYduct will provide personalized risk assessment tools and help identify precancero... CYduct Diagnostics, Inc., headquartered in Westport, Connecticut, develops, produces, and markets medical products for the assessment, identification, diagnosis and ultimately treatment of early-stage breast disease. CYduct will provide personalized risk assessment tools and help identify precancerous and cancerous lesions within the mammary ducts. The CYduct technology platforms will be single-use, proprietary, high-margin, high-volume suite of breast care products which assess, screen, detect, monitor and treat identifiable changes that distinguish variations in breast health. CYduct is committed to providing both women and clinicians with noninvasive and minimally invasive technology that will continue to accelerate the intraductal evolution and improvement in the ability to: 1) assess breast health risk, 2) monitor breast health, 3) identify the need for increased personalized risk surveillance and 4) provide the tools to monitor, diagnose/treat breast disease through visual examination (Breast Endoscopy) within the ductal system of the breast. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Carson City, Nevada, USA
Founded
-
CYduct Diagnostics Inc (PK) is listed in the Surgical,med Instr,apparatus sector of the OTCMarkets with ticker CYDX. The last closing price for CYduct Diagnostics (PK) was US$0.15. Over the last year, CYduct Diagnostics (PK) shares have traded in a share price range of US$ 0.127 to US$ 0.532.

CYduct Diagnostics (PK) currently has 5,240,857 shares in issue. The market capitalisation of CYduct Diagnostics (PK) is US$791,893.49 . CYduct Diagnostics (PK) has a price to earnings ratio (PE ratio) of -1.88.

CYDX Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120.01097.774607703280.14020.5320.14022640.38003552CS
260.024118.97637795280.1270.5320.1272890.38346426CS
52-0.3589-70.37254901960.510.5320.1274380.42191519CS
156-0.3589-70.37254901960.511.150.1277100.59223438CS
260-0.4689-75.62903225810.624.890.0610030.74906472CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FDVXFFenixOro Gold Corporation (CE)
US$ 0.03
(2,999,900.00%)
17.5k
MDVLQMedAvail Holdings Inc (CE)
US$ 0.0005
(49,900.00%)
1.22k
MOTSMotus GI Holdings Inc (CE)
US$ 0.0002
(19,900.00%)
4.67k
EEGIELine Entertainment Group Inc (CE)
US$ 0.0002
(19,900.00%)
11.2M
BRSIBallistic Recovery Systems Inc (CE)
US$ 0.0002
(19,900.00%)
18.55k
MHPCManufactured Housing Properties Inc (CE)
US$ 0.000001
(-100.00%)
100
MJDSMOJO Data Solutions Inc (CE)
US$ 0.000001
(-99.98%)
1.61k
VENGVision Energy Corporation (CE)
US$ 0.000001
(-99.96%)
6.64k
BORKBourque Industries Inc (CE)
US$ 0.000001
(-99.96%)
275k
WTRVWhite River Energy Corporation (CE)
US$ 0.0011
(-99.92%)
1,000
HMBLHUMBL Inc (PK)
US$ 0.0016
(-30.43%)
1.72B
PHILPHI Group Inc (PK)
US$ 0.0003
(50.00%)
1.03B
GNCPGNCC Capital Inc (CE)
US$ 0.000001
(0.00%)
702.1M
GMPRGourmet Provisions International Corporation (PK)
US$ 0.00015
(14,900.00%)
637.31M
RDARRaadr Inc (PK)
US$ 0.0018
(-10.00%)
518.88M

CYDX Discussion

View Posts
Thugmuffin Thugmuffin 3 years ago
$CYDX CYduct Diagnostics, Inc. Joins Connecticut's Biosciences CommunityPress Release | 05/09/2022

WESTPORT, CT / ACCESSWIRE / May 9, 2022 / CYduct Diagnostics, Inc. (OTC PINK:CYDX) ("CYduct") is pleased to announce it has joined BioCT, Connecticut's Biosciences Community.

Commenting on CYduct's membership into BioCT, Dominick Gatto, CYduct's Chief Executive Officer stated, "We look forward to utilizing the many resources available thru BioCT's network and its many members."

Mr. Gatto continued, "I am pleased to continue our growth and development within the biosciences community of our home state, Connecticut. It has been our goal to build CYduct from and within Connecticut, utilizing primarily Connecticut resources when possible." Our company is at the stage where innovative and strategic planning will assist in moving the company successfully forward, and the assistance found within the BioCT community will help us meet those plans and achieve our goals."

About BioCT:

BioCT is the bioscience industry voice for Connecticut, dedicated to growing a vibrant ecosystem by supporting innovation, collaboration, networking, education, talent engagement and advocacy. BioCT brings together companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people, to build a thriving bioscience community to improve patients' lives and public health, while driving economic growth. Additional information is available on BioCT's website at: www.bioct.org.

About CYduct Diagnostics, Inc.:

CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare markets across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at: www.CYductdx.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CYduct Diagnostics, Inc.
Investor Relations +1-888-545-9112
👍️0
AskMuncher AskMuncher 4 years ago
$CYDX CYduct Diagnostics, Inc. Announces OTC Ticker Symbol Change to "CYDX"
Press Release | 12/29/2020
WESTPORT, CT / ACCESSWIRE / December 29, 2020 / CYduct Diagnostics, Inc. (OTC PINK:SNDYD) is pleased to announce that FINRA has approved a change in the Company's stock symbol trading on the OTC Markets. Effective tomorrow, December 30, 2020, the Company's common shares will trade on the OTC Markets under the symbol "CYDX." The previous trading symbol was "SNDYD."

"We are excited to begin trading under our new 'CYDX' symbol and believe that the new ticker matches our goal of continuing to strategically reposition the Company and move the business forward," said Dom Gatto CEO of CYduct Diagnostics. "The symbol change aligns directly with our new corporate brand and will strengthen our visibility in the market, making it easier for current shareholders and prospective investors to find and follow the Company."

About CYduct Diagnostics, Inc.
CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare market across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at: www.cyductdx.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact
CYduct Diagnostics, Inc.
Investor Relations
(617) 360-9700

SOURCE: CYduct Diagnostics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/622430/CYduct-Diagnostics-Inc-Announces-OTC-Ticker-Symbol-Change-to-CYDX

👍️0
AskMuncher AskMuncher 4 years ago
$CYDX CYduct Diagnostics, Inc. Announces OTC Ticker Symbol Change to "CYDX"
Press Release | 12/29/2020
WESTPORT, CT / ACCESSWIRE / December 29, 2020 / CYduct Diagnostics, Inc. (OTC PINK:SNDYD) is pleased to announce that FINRA has approved a change in the Company's stock symbol trading on the OTC Markets. Effective tomorrow, December 30, 2020, the Company's common shares will trade on the OTC Markets under the symbol "CYDX." The previous trading symbol was "SNDYD."

"We are excited to begin trading under our new 'CYDX' symbol and believe that the new ticker matches our goal of continuing to strategically reposition the Company and move the business forward," said Dom Gatto CEO of CYduct Diagnostics. "The symbol change aligns directly with our new corporate brand and will strengthen our visibility in the market, making it easier for current shareholders and prospective investors to find and follow the Company."

About CYduct Diagnostics, Inc.
CYduct Diagnostics Inc. is a medical device company pursuing innovations within the women's healthcare market, primarily breast healthcare and wellness. CYduct is focused on breast health and wellness through new testing methods that prioritize clinical integrity and patient privacy and convenience. The Company's history is rooted in providing quality medical products to healthcare market across the United States. For more than 30 years, from medical schools to hospitals, physicians have relied on the Company to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products will be available on the Company's website at: www.cyductdx.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the Company, are forward-looking statements that involve significant risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. The inability to raise additional capital, and technical complications in research, product development and validation, among other things, could prevent the implementation of strategically significant plan(s) outlined above. The Company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the Company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Contact
CYduct Diagnostics, Inc.
Investor Relations
(617) 360-9700

SOURCE: CYduct Diagnostics, Inc.

👍️0
Renee Renee 4 years ago
Effective Dec. 30,2020 SNDYD will change to CYDX:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Renee Renee 4 years ago
SNDY: effective Dec. 1,2020 Solos Endoscopy Inc. will change to CYduct Diagnostics Inc. and a one for 250 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
whytestocks whytestocks 4 years ago
BREAKING NEWS: $SNDY Solos Endoscopy, Inc. Acquires Assets of CYduct, LLC

WESTPORT, CT / ACCESSWIRE / November 20, 2020 / Solos Endoscopy, Inc. (OTC PINK:SNDY) is pleased to announce that Solos' CEO and majority shareholder, Dominick Gatto, has contributed to Solos the extensive research and intellectual property of CYduct LLC, which he also controls. These assets...

In case you are interested SNDY - Solos Endoscopy, Inc. Acquires Assets of CYduct, LLC
👍️0
CrazyC CrazyC 4 years ago
News is out...

https://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopys-MammoViewR-Now-for-use-with-Low-Temperature-Sterilization-System?id=274205

Solos Endoscopy's MammoView(R) Now for use with Low Temperature Sterilization System

WESTPORT, CT / ACCESSWIRE / September 16, 2020 / Solos Endoscopy, Inc. (OTC PINK:SNDY) is pleased to announce it has completed the compatibility testing of its MammoView product line with The STERIS V-PRO 1 Low Temperature Sterilization System.

"Solos Endoscopy continues to strive and provide the latest reprocessing methods for its customers.", stated Dominick Gatto, Chief Executive Officer. "In response to our customer's needs, we had our MammoView products tested for compatibility with the STERIS V-PRO Low Temperature Sterilization System." said Gatto. He further stated, "we are confident this additional sterilization method will expand our customer reach and enhance the efficiency of the MammoView products for our customers".

Solos MammoView Breast Endoscopy System employs advanced microendoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where most of the breast cancers arise. Mammary ductoscopy is designed to provide physicians the means to detect, diagnose, and treat breast disease years before surgery, physical exams or other external imaging can reveal evidence of the disease.

About Solos Endoscopy, Inc.: Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CONTACT:

Solos Endoscopy, Inc.
Investor Relations
(617) 360-9700

SOURCE: Solos Endoscopy, Inc.
👍️0
CaoPanShou CaoPanShou 4 years ago
India sales may be good as India is very anti China now. If SNDY can ensure they are not sourcing their parts in China.
👍️0
CaoPanShou CaoPanShou 4 years ago
Unusual spike in volume, maybe news coming?
👍️0
Ablivious Ablivious 4 years ago
Pretty good volume today $SNDY

GLTA
👍️0
CaoPanShou CaoPanShou 5 years ago
$SNDY Testing highs again with volume spike!
👍️0
CaoPanShou CaoPanShou 5 years ago
Broke an old resistance level today. Increasing interest here each month.
👍️0
CaoPanShou CaoPanShou 5 years ago
Definatley some tension building here. Trading almost everyday.
👍️0
CaoPanShou CaoPanShou 5 years ago
Just going about business. Not a P&D, so no useless fluff PRs.
👍️0
Vwatzisface Vwatzisface 5 years ago
Hmm what’s going on here today
👍️0
CaoPanShou CaoPanShou 5 years ago
WESTPORT, CT / ACCESSWIRE / February 27, 2020 / Solos Endoscopy, Inc. (SNDY) is pleased to announce its results of operations for the year ended December 31, 2019.

The financial results reported represent a year-over-year comparison of 2019 to 2018. Total revenues increased over 5% for the year to $194,000 compared to $184.000 for 2018. Gross Profit increased to $132,000 compared to $93,000 for the previous year. Operating expense remained equal to that of 2018.
👍️0
EmptyBones EmptyBones 5 years ago
SNDY broke 50k in total assets lmao

https://backend.otcmarkets.com/otcapi/company/financial-report/240678/content
👍️0
CaoPanShou CaoPanShou 5 years ago
Replying to a comment that's 8 years old?
👍️0
CaoPanShou CaoPanShou 5 years ago
Did I miss some news? Sudden interest here.
👍️0
CaoPanShou CaoPanShou 5 years ago
always interested. glad to see things slowly growing.
Takes time to fix a mess like the previous management made, but they are doing it.
👍️0
CrazyC CrazyC 5 years ago
SNDY - News is out (if anyone really cares)...

https://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy-Inc-Will-Look-to-Become-a-Womens-Healthcare-Focused-Company?id=251235

Solos Endoscopy, Inc. Will Look to Become a Women’s Healthcare Focused Company

Westport, CT, Jan. 14, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce its expanded strategic focus - the market for breast cancer related products and services, which domestically approaches $10 billion per year.

“Solos’ core product line, MammoView, has shown great promise recently within the Unites States, as well as internationally,” stated Dominick Gatto, Chief Executive Officer, and it now will be the centerpiece of the Company's Breast Endoscopy platform. MammoView gives physicians the ability to perform minimally invasively procedures that can examine a patient's mammary ducts to monitor, diagnose and treat abnormal breast tissue at a very early stage.

"The Company plans to leverage its MammoView intraductal technology platform and through a combination of targeted intellectual property acquisitions and subsequent R&D efforts, plus new equity fundraising to provide us with the necessary additional capital. We intend to develop a suite of new products and technologies that address the need for improved breast health screening, and monitoring, while fostering early breast cancer detection and facilitating better treatment options,” said Gatto.

About Solos Endoscopy, Inc.:

Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, the company's need for substantial additional capital which it may not be able to obtain on reasonable terms, if at all, and those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Elise Grubb
8003886445 x4
egrubb@solosendoscopy.com
👍️0
Biddock1 Biddock1 5 years ago
Yup very little buzz also thing looks good just need some bid support.
👍️0
CrazyC CrazyC 5 years ago
We have some volume and the PPS is increasing... Peeps are finally realizing that SNDY is coming to life...
👍️0
Biddock1 Biddock1 5 years ago
They are putting a steady stream of news this should catch on soon with such a small float.
👍️0
CrazyC CrazyC 5 years ago
SNDY - News is out...

https://www.otcmarkets.com/stock/SNDY/news/Solos-Endoscopy-Inc-Appoints-Distributor-to-Expand-Their-MammoView-Sales-Into-India?id=243553

Solos Endoscopy, Inc. Appoints Distributor to Expand Their MammoView Sales Into India

Press Release | 10/17/2019

WESTPORT, CT, Oct. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce it has begun shipping products to its newly appointed India distributor, Shreyaas Healthcare. This is a follow up to the successful introduction, by Shreyaas Healthcare, of Solos’ MammoView ductoscopy products at the 8th Annual Conference of Association of Breast Surgeons of India (ABSICON),

“We could not have hoped for a better partnership in India, than the one we have with Shreyaas Healthcare. With their assistance, we expect to build a strong relationship with the breast physicians who are actively fighting the battle against breast cancer in India. Our growth opportunity within this market is tremendous,” stated Joe Gassman, International Sales Consultant for Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy Inc. has long provided quality healthcare instruments to hospitals across the United States. For more than 30 years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.

Investor Relations

(617) 360-9700

👍️0
CaoPanShou CaoPanShou 5 years ago
Signs of life. New product at show.
👍️0
zandant zandant 5 years ago
At least they got that crooked father and daughter team out of the picture.
👍️0
CaoPanShou CaoPanShou 5 years ago
Slowly getting things together. Future looking brighter.
👍️0
CrazyC CrazyC 5 years ago
SNDY - News is out..

https://backend.otcmarkets.com/otcapi/company/dns/news/document/37258/content

Solos Endoscopy, Inc. Reports Elimination of its Derivative Liability

WESTPORT, July 23, 2019 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) a provider of quality medical devices to hospitals and clinics across the country, has announced that as of June 30, 2019, all remaining outstanding shares of its Series B Preferred Stock have been converted into shares of Common Stock. Consequently the Company will eliminate from its June 30, 2019 balance sheet the remaining $910,000 Derivative Liability related to such Stock.

Chief Executive Officer Dom Gatto stated, “This is another great step for the company as we continue to strengthen our capital structure. When current management took control in May 2017, the Company had a Derivative Liability of approximately $2,400,000. That Liability now has been completely removed from our Balance Sheet. We believe our efforts will clear the way for our future plans and will create significant value for our shareholders."

About Solos Endoscopy, Inc.:
Solos Endoscopy Inc. has long provided quality healthcare instruments to Hospitals across the United States. For more than 30 Years, from medical schools to hospitals, surgeons have relied on Solos Endoscopy to develop medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its line of products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding the potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Solos Endoscopy, Inc.

Investor Relations
(617) 360-9700
👍️0
mrglobal mrglobal 6 years ago
Yesterday
https://backend.otcmarkets.com/otcapi/company/financial-report/204689/content
and today
https://backend.otcmarkets.com/otcapi/company/financial-report/204820/content
👍️0
Vwatzisface Vwatzisface 6 years ago
Good news today?
👍️0
tripil7z tripil7z 6 years ago
$SNDY filled .0026 thnx wackers
👍️0
CaoPanShou CaoPanShou 6 years ago
The important bit... Mr. Gatto added:
“These are additional steps in restructuring the Company’s capitalization and management. We have removed the final member of the previous management team from the operations of the Company. We look to further improve Solos’ capital structure, which has been a major impediment to improving the Company’s financial health, and to attract new management individuals with hands-on industry experience and proven leadership.”
👍️0
CaoPanShou CaoPanShou 6 years ago
There was a doc drop today at OTC.

$SNDY
👍️0
CaoPanShou CaoPanShou 6 years ago
$SNDY moved 4 mil shares today. Something is going on. New management may be making a move and someone inside knows whats up.
👍️0
CaoPanShou CaoPanShou 6 years ago
None of my usual sources show any news, someone must know something...
👍️0
CaoPanShou CaoPanShou 6 years ago
What woke $SNDY up today?
👍️0
tripil7z tripil7z 6 years ago
$SNDY grabbing some .003s here
👍️0
MattyTrader MattyTrader 6 years ago
pR today
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
will be
👍️0
Hulk Hogan is God Hulk Hogan is God 7 years ago
The run down?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
SNDY~~the run is here
👍️0
SRV1975 SRV1975 7 years ago
Nice to see the Attny letter.... Feels like things are about to start here!
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
SNDY~~FLOAT 45M, O/S 144M , CURRENT NOW
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
SNDY ,lets run this monsta folks Attorney Letter with Respect to Current Information - Attorney Letter with Respect to Current Information

https://www.otcmarkets.com/stock/SNDY/disclosure
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
SNDY is CURRENT NOW,,will go hard here, https://www.otcmarkets.com/stock/SNDY/disclosure
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
SNDY~~READY to go
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 7 years ago
SNDY~~.0057, buyyyyy,,running,FLOAT 48k
👍️0
CaoPanShou CaoPanShou 7 years ago
Has there been any communication from the new management? Really hard to buy shares right now, couldn't get a complete order filled. This could pop very quickly on any news.
👍️0
MichaelKane MichaelKane 7 years ago
More filings today
👍️0

Your Recent History

Delayed Upgrade Clock